Nuvo Research Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: axial who wrote (9798)	6/14/2002 9:10:28 AM
From: Montana Wildhack	Read Replies (3) of 14101

From Michael on stockhouse: (the bolding is mine) Friday June 14, 07:25 AM U.S. firm terminates osteoarthritis deal NEW YORK (Reuters) - Dimethaid Research says it has terminated a sales and marketing deal with Provalis Healthcare for distribution of a drug used to treat pain associated with osteoarthritis. In January of last year, the company entered into a deal with Provalis (LSE: PRO.L - news) awarding the British company exclusive rights to market and distribute the Pennsaid drug in the United Kingdom where some 7 million people suffer from osteoarthritis. In exchange for the rights, Provalis was expected to meet minimum sales targets by March. Dimethaid was entitle to terminate the contract if those targets were not achieved. "We fully expected Pennsaid to be achieving greater sales and market penetration in the United Kingdom than has been the case to date," Dimethaid said in a release on Friday. Provalis could not be immediately reached for comment.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next